Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
Abstract Objective The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole. Methods The retrospective study cohort comprised 40 patients diagnosed wit...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-024-06437-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559113230712832 |
|---|---|
| author | Yin Cao Jun Liang Biao Dai Feng Shan Qingrong Xia |
| author_facet | Yin Cao Jun Liang Biao Dai Feng Shan Qingrong Xia |
| author_sort | Yin Cao |
| collection | DOAJ |
| description | Abstract Objective The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole. Methods The retrospective study cohort comprised 40 patients diagnosed with first-episode SCZ (SCZ group) and 40 healthy individuals (control group). Quantitative analyses were conducted on five complement factors, namely complement component 1 (C1), C2, C3, C4, and the 50% hemolytic complement (CH50). Baseline serum complement factor levels were compared between the SCZ and control groups. Patients diagnosed with SCZ underwent a 4-week treatment regimen with aripiprazole. The severity of psychiatric symptoms in these patients was assessed using the Positive and Negative Symptom Scale (PANSS) and the Brief Psychiatric Rating Scale-18 Item Version (BPRS). Comparative analyses were conducted on PANSS and BPRS scores, as well as serum complement factor levels, both prior to (pre-treatment group) and following aripiprazole administration (post-treatment group). Pearson’s correlation test was employed to evaluate the relationships between changes in serum complement factor levels and the reduction rates of PANSS/BPRS scores. Results At baseline, patients with SCZ exhibited significantly elevated levels of C1, C2, C3, C4, and CH50 compared to the control group (P < 0.05). Moreover, following treatment, there was a significant reduction in the PANSS total score, positive symptom score, negative symptom score, and BPRS score in the post-treatment group compared to the pre-treatment group (P < 0.05). Furthermore, patients in the post-treatment group exhibited a significant reduction in serum levels of C2, C3, and C4, alongside a significant increase in the serum level of CH50 compared to those in the pre-treatment group (P < 0.05). Additionally, the baseline serum C2 levels and the variations in serum C2 levels pre- and post-treatment exhibited a negative correlation with the reduction rate of PANSS/BPRS scores (P < 0.05). Similarly, both the baseline serum C3 levels and the changes in serum C3 levels pre- and post-treatment were negatively correlated with the reduction rate of PANSS/BPRS scores (P < 0.05). Conclusion Baseline serum levels of C2 and C3, as well as their variations pre- and post-treatment, may serve as biomarkers for predicting clinical efficacy in patients with first-episode SCZ undergoing treatment with aripiprazole. |
| format | Article |
| id | doaj-art-0823500523864bcebeb32444be596e4c |
| institution | Kabale University |
| issn | 1471-244X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj-art-0823500523864bcebeb32444be596e4c2025-01-05T12:42:50ZengBMCBMC Psychiatry1471-244X2024-12-012411810.1186/s12888-024-06437-0Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatmentYin Cao0Jun Liang1Biao Dai2Feng Shan3Qingrong Xia4Affiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAffiliated Psychological Hospital of Anhui Medical UniversityAbstract Objective The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole. Methods The retrospective study cohort comprised 40 patients diagnosed with first-episode SCZ (SCZ group) and 40 healthy individuals (control group). Quantitative analyses were conducted on five complement factors, namely complement component 1 (C1), C2, C3, C4, and the 50% hemolytic complement (CH50). Baseline serum complement factor levels were compared between the SCZ and control groups. Patients diagnosed with SCZ underwent a 4-week treatment regimen with aripiprazole. The severity of psychiatric symptoms in these patients was assessed using the Positive and Negative Symptom Scale (PANSS) and the Brief Psychiatric Rating Scale-18 Item Version (BPRS). Comparative analyses were conducted on PANSS and BPRS scores, as well as serum complement factor levels, both prior to (pre-treatment group) and following aripiprazole administration (post-treatment group). Pearson’s correlation test was employed to evaluate the relationships between changes in serum complement factor levels and the reduction rates of PANSS/BPRS scores. Results At baseline, patients with SCZ exhibited significantly elevated levels of C1, C2, C3, C4, and CH50 compared to the control group (P < 0.05). Moreover, following treatment, there was a significant reduction in the PANSS total score, positive symptom score, negative symptom score, and BPRS score in the post-treatment group compared to the pre-treatment group (P < 0.05). Furthermore, patients in the post-treatment group exhibited a significant reduction in serum levels of C2, C3, and C4, alongside a significant increase in the serum level of CH50 compared to those in the pre-treatment group (P < 0.05). Additionally, the baseline serum C2 levels and the variations in serum C2 levels pre- and post-treatment exhibited a negative correlation with the reduction rate of PANSS/BPRS scores (P < 0.05). Similarly, both the baseline serum C3 levels and the changes in serum C3 levels pre- and post-treatment were negatively correlated with the reduction rate of PANSS/BPRS scores (P < 0.05). Conclusion Baseline serum levels of C2 and C3, as well as their variations pre- and post-treatment, may serve as biomarkers for predicting clinical efficacy in patients with first-episode SCZ undergoing treatment with aripiprazole.https://doi.org/10.1186/s12888-024-06437-0First-episode schizophreniaAripiprazoleComplement factorPANSSEfficacy |
| spellingShingle | Yin Cao Jun Liang Biao Dai Feng Shan Qingrong Xia Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment BMC Psychiatry First-episode schizophrenia Aripiprazole Complement factor PANSS Efficacy |
| title | Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment |
| title_full | Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment |
| title_fullStr | Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment |
| title_full_unstemmed | Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment |
| title_short | Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment |
| title_sort | peripheral blood complement factors c2 and c3 as biomarkers of clinical efficacy in patients with first episode schizophrenia after aripiprazole treatment |
| topic | First-episode schizophrenia Aripiprazole Complement factor PANSS Efficacy |
| url | https://doi.org/10.1186/s12888-024-06437-0 |
| work_keys_str_mv | AT yincao peripheralbloodcomplementfactorsc2andc3asbiomarkersofclinicalefficacyinpatientswithfirstepisodeschizophreniaafteraripiprazoletreatment AT junliang peripheralbloodcomplementfactorsc2andc3asbiomarkersofclinicalefficacyinpatientswithfirstepisodeschizophreniaafteraripiprazoletreatment AT biaodai peripheralbloodcomplementfactorsc2andc3asbiomarkersofclinicalefficacyinpatientswithfirstepisodeschizophreniaafteraripiprazoletreatment AT fengshan peripheralbloodcomplementfactorsc2andc3asbiomarkersofclinicalefficacyinpatientswithfirstepisodeschizophreniaafteraripiprazoletreatment AT qingrongxia peripheralbloodcomplementfactorsc2andc3asbiomarkersofclinicalefficacyinpatientswithfirstepisodeschizophreniaafteraripiprazoletreatment |